Inside Health Folgen

In the UK, around a third of British children have tooth decay. Just among the under-fives, it's a quarter - a figure that rises significantly in the most deprived areas.Tooth decay can cause speech development issues, embarrassment for children and in 2023, 15 million school days were missed due to tooth pain or treatment. There’s a financial cost too – in 2023 in England alone tooth extractions under a general anaesthetic cost the NHS £41 million.And it's totally preventable. So, how can we stop teeth rotting in the first place? One way initiative announced by the new Labour government is to expand supervised toothbrushing sessions to more children. We find out how these work with Oral Health Team Lead Helen Bullingham who supports nurseries and schools in East Sussex to deliver these programmes.But what about the evidence to support this intervention? Zoe Marshman, Professor of Dental Public Health at University of Sheffield, explains her findings and dental hygienist and researcher at King's College London Dr Claire McCarthy describes what parents should be doing, in an ideal world, at home. And finally, what role does sugar play and how can we get consumption down? Dr Nina Rogers from the Population Health Innovation Lab at the London School of Hygiene & Tropical Medicine explains her findings into the impact of the Sugar Drinks Industry Levy introduced in 2018.Presenter: James Gallagher Producers: Hannah Robins Content Editor: Holly SquireInside Health is a BBC Wales & West production for Radio 4, produced in partnership with The Open University.

Olympic cyclist Sir Chris Hoy is calling for more prostate cancer testing after he was diagnosed with terminal cancer. Prostate cancer can often present without symptoms, and for people like Sir Chris, this can mean it isn't diagnosed until it has spread and become incurable. Unlike breast, bowel, or cervical cancer, there is currently no national screening programme that routinely invites men for prostate cancer testing. Instead, men over 50 can request what's known as a PSA blood test from their GP, but it's not automatically offered. Sir Chris wants that to change and is calling for the test to be made more easily available for men under 50, especially those with a family history of prostate cancer. But, expanding prostate screening is a divisive issue. While it could help detect cancer earlier in some cases, there are potential drawbacks. Inside Health's James Gallagher talks with Professor Frank Chinegwundoh, Consultant Urological Surgeon at Barts Health NHS Trust, Professor Hashim Ahmed, Chair of Urology at Imperial College London and Inside Health's resident GP Dr Margaret McCartney about the evidence for and against prostate cancer screening - and whether Sir Chris's campaign could and should change the guidance. This programme was produced in partnership with The Open University.Presenter: James Gallagher Producer: Tom Bonnett Editor: Holly Squire

The first drugs to slow Alzheimer's progression have been making headlines around the world. For researchers in the field, the arrival of these two therapies called Lecanemab and Donanemab is testament to decades of advancements in the field of Alzheimer's research because for the first time they go further than modifying the symptoms and have been shown in trials to slow down cognitive decline. For patients and families these treatments offer hope that the amount of quality time they'll have together could be lengthened. Around the world regulatory bodies are weighing up their effectiveness, safety and cost. In the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lecanemab and Donanemab for use but the National Institute for Health and Care Excellence (NICE) rejected them for use in the NHS on the basis the benefit to patients did not outweight the cost, although they could still be available privately.Presenter James Gallagher examines the decision with Professor of Public Health Carol Brayne from the University of Cambridge and neuroscientist Professor Tara Spires-Jones from the University of Edinburgh. Then, looking forward, he meets scientists searching for future treatments including Dr Emma Mead, chief scientist at the Alzheimer's UK Drug Discovery Institute at the University of Oxford, Dr Ashvini Keshavan, co-lead of University College London's ADAPT blood biomarker trial, Selina Wray, Professor of Molecular Neuroscience and Alzheimer's Research UK Senior Research Fellow at University College London, and UK Dementia Research Institute Emerging Leader Dr Claire Durrant.This programme was produced in partnership with The Open University.Presenter: James Gallagher Producer: Tom Bonnett Editor: Holly Squire